Alfuzosin - CAS 81403-80-7
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Alfuzosin
Catalog Number:
81403-80-7
Synonyms:
Alfuzosina;Alfuzosine;Xatral;2-Furancarboxamide,N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-;N-[3-[N-(4-Amino-6,7-dimethoxyquinazolin-2-yl)-N-(methyl)amino]propyl]tetrahydrofuran-2-carboxamide;SL 77499;Alfuzosinum
CAS Number:
81403-80-7
Description:
Alfuzosin is a pharmaceutical drug of the alpha-1 blocker class. It works by relaxing the muscles in the prostate and bladder neck. It is used to treat benign prostatic hyperplasia (BPH). It offers an alternative to prostatectomy in patients who require surgery but are unfit for this treatment, and in patients requiring symptomatic relief while awaiting surgery. It is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. It was approved by the FDA for treatment of BPH in June 2003. It has been approved the listing.
Molecular Weight:
389.45
Molecular Formula:
C19H27N5O4
Quantity:
Grams to Kilograms
Quality Standard:
In-house standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
InChI:
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
InChIKey:
WNMJYKCGWZFFKR-UHFFFAOYSA-N
Targets:
Adrenergic Receptor
Current Developer:
Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. It was approved by the FDA for treatment of BPH in June 2003. It has been approved the listing.
Chemical Structure
CAS 81403-80-7 Alfuzosin

Related Adrenergic Receptor Products


CAS 208992-74-9 Fiduxosin hydrochloride

Fiduxosin hydrochloride
(CAS: 208992-74-9)

Fiduxosin hydrochloride is an alpha(1)-adrenoceptor antagonist used for the treatment of benign prostatic hyperplasia.

CAS 86347-14-0 Medetomidine

Medetomidine
(CAS: 86347-14-0)

Medetomidine is a potent, highly selective α2-adrenoceptor agonist, which Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively. It is often ...

CAS 67346-49-0 (R,R)-Formoterol

(R,R)-Formoterol
(CAS: 67346-49-0)

(R,R)-Formoterol is a long acting beta-adrenoceptor agonist acts as a novel highly β2-selective adrenergic agonist and holds promise as a β2-agonist that could ...

CAS 65576-45-6 Asenapine

Asenapine
(CAS: 65576-45-6)

Asenapine is an atypical antipsychotic multireceptor neuroleptic drug by combining serotonin (5HT2) and dopamine (D2) receptor antagonist; structurally related ...

CAS 13392-18-2 Fenoterol

Fenoterol
(CAS: 13392-18-2)

Fenoterol, a phenol derivative, is a β2-adrenoceptor agonist and could be used as a bronchodilator and an antiasthmatic.

CAS 329-65-7 DL-Adrenaline

DL-Adrenaline
(CAS: 329-65-7)

DL-Adrenaline is a hormone and a neurotransmitter secreted by the medulla of the adrenal glands.

CAS 148849-67-6 Ivabradine HCl

Ivabradine HCl
(CAS: 148849-67-6)

Ivabradine HCl, a new If inhibitor with IC 50 of 2.9 μM which acts specifically on the pacemaker activity of the sinoatrial node, is a pure heart rate lowering ...

CAS 51781-21-6 Carteolol Hydrochloride

Carteolol Hydrochloride
(CAS: 51781-21-6)

Carteolol HCl is a β-adrenoceptor antagonist, used for the treatment of glaucoma.

CAS 753498-25-8 Indacaterol Maleate

Indacaterol Maleate
(CAS: 753498-25-8)

Indacaterol is an ultra-long-acting β-adrenoceptor agonist with pKi of 7.36.

CAS 59803-98-4 Brimonidine

Brimonidine
(CAS: 59803-98-4)

Brimonidine is α2-Adrenoceptor agonist. It is a drug used as eye drops to treat open-angle glaucoma or ocular hypertension. It acts via decreasing synthesis of ...

CAS 21498-08-8 Lofexidine hydrochloride

Lofexidine hydrochloride
(CAS: 21498-08-8)

Lofexidine hydrochloride is the hydrochloride salt form of Lofexidine. Lofexidine, an analogue of clonidine, is an α2A-adrenergic receptor agonist for the treat...

VIBEGRON
(CAS: 1190389-15-1)

This active molecular is a selective Beta 3 Adrenergic Receptor Agonist and was developed by Kyorin Pharmaceutical for the treatment of OAB (Overactive Bladder)...

CAS 74191-85-8 Doxazosin

Doxazosin
(CAS: 74191-85-8)

Doxazosin is a quinazoline-derivative and long-lasting α1 adrenergic receptor blocker. It inhibits the binding of norepinephrine, which is released from sympath...

CAS 555-30-6 Methyldopa

Methyldopa
(CAS: 555-30-6)

Methyldopa (Aldomet) is a DOPA decarboxylase competitive inhibitor with an ED50 of 21.8 mg/kg.

CAS 29122-68-7 Atenolol

Atenolol
(CAS: 29122-68-7)

Atenolol, with antianginal and antiarrhythmic properties, it is a cardioselective beta-adrenergic blocker and used in hypertension control.

CAS 959-24-0 Sotalol hydrochloride

Sotalol hydrochloride
(CAS: 959-24-0)

Sotalol hydrochloride is a non-selective beta adrenoceptor antagonist and potassium channel blocker (IC50 = 43 μM)

CAS 70359-46-5 Brimonidine Tartrate

Brimonidine Tartrate
(CAS: 70359-46-5)

Brimonidine Tartrate is a highly selective α-adrenergic receptor agonist with EC50 of 0.45 nM for the α2A adrenoreceptor, and used to treat open-angle glaucoma ...

CAS 530-08-5 Isoetarine

Isoetarine
(CAS: 530-08-5)

Isoetarine is a selective adrenergic beta-2 agonist. It is used as fast acting bronchodilator for emphysema, bronchitis and asthma. It has been listed.

CL-316243
(CAS: 183720-02-7)

CL-316243 is a potent and highly selective β3-adrenoceptor agonist (EC50 = 3 nM) with > 10000-fold selective over β1 and β2 receptors. CL 316243 possesses anti-...

CAS 71576-40-4 Aptazapine

Aptazapine
(CAS: 71576-40-4)

Aptazapine is a tetracyclic antidepressant. It was assayed in clinical trials for the treatment of depression in the 1980s but was never marketed. Aptazapine is...

Reference Reading


1.Assessment of column selection systems using Partial Least Squares.
Žuvela P1, Liu JJ2, Plenis A3, Bączek T3. J Chromatogr A. 2015 Nov 13;1420:74-82. doi: 10.1016/j.chroma.2015.09.085. Epub 2015 Oct 1.
Column selection systems based on calculation of a scalar measure based on Euclidean distance between chromatographic columns, suffer from the same issue. For diverse values of their parameters, identical or near-identical values can be calculated. Proper use of chemometric methods can not only provide a remedy, but also reveal underlying correlation between them. In this work, parameters of a well-established column selection system (CSS) developed at Katholieke Universiteit Leuven (KUL CSS) have been directly correlated to parameters of selectivity (retention time, resolution, and peak/valley ratio) toward pharmaceuticals, by employing Partial Least Squares (PLS). Two case studies were evaluated, separation of alfuzosin, lamotrigine, and their impurities, respectively. Within them, comprehensive correlation structure was revealed, which was thoroughly interpreted, confirming a causal relationship between KUL parameters and parameters of column performance.
2.Formulation and evaluation of gastroretentive controlled release tablets of alfuzosin hydrochloride.
Rudraswamy-Math NR1, Gupta VR1. Pak J Pharm Sci. 2015 Nov;28(6):2147-52.
Alfuzosin hydrochloride is a novel drug used in the treatment of urinary incontinency. The purpose of this research was to develop controlled release floating matrix formulations of Alfuzosin HCl. Floating matrix tablets of Alfuzosin HCl were prepared using hydroxypropyl methylcellulose (HPMC), Polyethylene oxide (PEO), Carbopol 971P NF polymer (Direct compressible) and Blend of Polyvinyl Acetate and Povidone 30 (80:19:1(0.8% sodium laury sulfate and 0.2% silica)). Combination of citric acid and sodium bicarbonate were also used as gas forming agent. Matrix formulations were prepared by direct compression method and evaluated for floating, in vitro drug release profile and swelling characteristics. The mechanism of drug release was found to follow non-Fickian or anomalous type. The data obtained from the invitro release studies demonstrated that the floating matrix tablets containing HPMC 100K CR (controlled-release) and carbopol along with sodium CMC were found to sustain the release of drug over a period of 12 hours.
3.Temperature influencing permeation pattern of alfuzosin: an investigation using DoE.
Pattnaik S1, Swain K2, Rao JV2, Varun T2, Mallick S3. Medicina (Kaunas). 2015;51(4):253-61. doi: 10.1016/j.medici.2015.07.002. Epub 2015 Jul 30.
BACKGROUND AND OBJECTIVE: There has been relatively little investigation of the effect of temperature on skin permeation compared to other methods of penetration enhancement. A principal physicochemical factor which controls the passive diffusion of a solute from a vehicle into the skin arises from the skin temperature. The aim of this ex vivo study was to probe into the effect of heat on transdermal absorption of alfuzosin hydrochloride from ethyl cellulose-polyvinyl pyrrolidone (EC-PVP) based transdermal systems.
4.Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Forbes A1, Anoopkumar-Dukie S2, Chess-Williams R1, McDermott C1. Prostate. 2016 Feb 16. doi: 10.1002/pros.23167. [Epub ahead of print]
BACKGROUND: Some α1 -adrenoceptor antagonists possess anti-cancer actions that are independent of α1 -adrenoceptors and the aim of these studies was to assess the relative cytotoxic potencies of α1 -adrenoceptor antagonists and the mechanisms involved in these actions.